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Objective: To assess the cost utility of early
psychosocial intervention for patients with Alzheimer’s
disease and their primary caregivers.
Design: Cost utility evaluation alongside a multicentre,
randomised controlled trial with 3 years of follow-up.
Setting: Primary care and memory clinics in five
Danish districts.
Participants: 330 community-dwelling patients and
their primary caregivers.
Intervention: Psychosocial counselling and support
lasting 8–12 months after diagnosis and follow-up at
3, 6, 12 and 36 months in the intervention group or
follow-up only in the control group.
Main outcome measures: The primary outcome
measure was the cost of additional quality-adjusted life
years (QALYs). Costs were measured from a societal
perspective, including the costs of healthcare, social
care, informal care and production loss. QALYs were
estimated separately for the patient and the caregiver
before aggregation for the main analysis.
Results: None of the observed cost and QALY
measures were significantly different between the
intervention and control groups, although a tendency
was noted for psychosocial care leading to cost
increases with informal care that was not outweighed
by the tendency for cost savings with formal care. The
probability of psychosocial intervention being cost-
effective did not exceed 36% for any threshold value.
The alternative scenario analysis showed that the
probability of cost-effectiveness increased over the
range of threshold values used if the cost perspective
was restricted to formal healthcare.
Conclusions: A multifaceted, psychosocial
intervention programme was found unlikely to be cost-
effective from a societal perspective. The
recommendation for practice in settings that are similar
to the Danish setting is to provide follow-up with
referral to available local support programmes when
needed, and to restrict large multifaceted intervention
programmes to patients and caregivers with special
needs until further evidence for cost-effectiveness
emerges.
Trial registration: The study was registered in the
Clinical Trial Database as ISRCTN74848736.
INTRODUCTION
According to the 2010 World Alzheimer’s
Report, more than 36 million people are
living with dementia, and the expectations
are that this number will have tripled by
2050.1 The associated economic impact is
estimated to approach €500 billion/year, and
to increase in proportion to the number of
people living with dementia.
Alzheimer’s disease (AD) accounts for
approximately half of all cases of dementia.2
It is a progressive and irreversible disease,
and even in the early phase, there is a sub-
stantial need for formal as well as informal
care. A recent literature review demonstrated
that the annual cost of care for mild AD
ranged from approximately €4000 to
approximately €40 000.3 Although the com-
position of these costs varied substantially
Strengths and limitations of this study
▪ Cost-utility analysis of a psychosocial interven-
tion for individuals with newly diagnosed demen-
tia and their relative based on a randomized
controlled trial with 36 months of follow-up.
▪ Relatively high response rates combined with
detailed register data from national registries
provide comprehensive cost and utility data.
▪ The health utility of the patients was proxy rated,
which has been shown to potentially imply an
underestimation.
▪ The validity of the measurement of informal care
warrants some consideration.
Søgaard R, Sørensen J, Waldorff FB, et al. BMJ Open 2014;4:e004105. doi:10.1136/bmjopen-2013-004105 1
Open Access Research
across studies, it is clear that the cost burden of this
disease had impacts far beyond the healthcare sector.
Medical costs were found to constitute between 10%
and 56% of the total costs, whereas non-medical costs
constituted between 6% and 51% and the costs of infor-
mal care constituted between 8% and 81%.
Until recently, the literature on effective management
strategies for mild AD has focused on pharmacological
treatment. However, the authors of a systematic literature
review concluded that non-pharmacological strategies
are useful, versatile and potentially cost-effective
approaches to improve outcomes.4 One such approach
was developed as part of the Danish Alzheimer’s
Intervention Study (DAISY) in 2004. Practitioners in the
ﬁelds of geriatrics, psychiatry, neurology, psychology,
care science, family medicine and law were involved in
developing a psychosocial, supportive intervention to be
tested in a randomised controlled trial.5 Clinical evalu-
ation after 1 year of follow-up demonstrated no overall
effect of the intervention, although it was concluded
that longer term follow-up was needed.6 However, in a
qualitative evaluation of the study, patients and care-
givers indicated that they found the intervention stimu-
lating and rewarding and that it helped them to ﬁnd
new ways to cope with the challenges of the disease.7
Now, after 3 years of follow-up, a long-term evaluation is
reported in the current issue of this journal and con-
cludes that there is no difference in clinical outcomes.8
The cost-effectiveness of non-pharmacological manage-
ment of AD obviously relies on the clinical efﬁcacy and
on the cost consequences. Even if non-pharmacological
management strategies fail to demonstrate the clinical
beneﬁts, there could be a rationale for adopting them if
they address the escalating costs of AD. In particular,
studies in the North American setting have shown that
caregiver support could delay nursing home place-
ment,9 10 although other studies have not conﬁrmed this
ﬁnding.11 12
The European literature on the cost-effectiveness of
non-pharmacological therapies for the treatment of mild
AD appears to be very limited. The objective of this
study was to assess the long-term cost utility of an early
and intensive multifaceted, psychosocial intervention
with follow-up support versus follow-up support alone
for patients with AD and their primary caregivers from a
societal perspective.
METHODS
Study design and intervention
The study was conducted alongside the randomised con-
trolled multicentre trial of DAISY, which has been previ-
ously described in detail.5 Brieﬂy, the trial included 330
dyads of patients and their primary caregivers, who were
randomised to an intensive, multicomponent, semitai-
lored psychosocial intervention programme with coun-
selling, education and support (psychosocial care, 163
dyads) or to structured and systematic follow-up support
(usual care, 167 dyads) and followed for 3 years. The
inclusion criteria for the dyads were based on the char-
acteristics of the patient and comprised age ≥50 years,
diagnosis of AD, mixed AD diagnosis and vascular
disease or dementia with Lewy bodies within the past
12 months, Mini-Mental State Examination score ≥20
and possession of a primary caregiver who was willing to
participate in the study. Institutionalised patients and
patients with severe comorbidity were excluded. The psy-
chosocial intervention was composed of individual and
group-based counselling sessions using a constructivist
approach, telephone counselling to the patient or the
caregiver, a two-course series of ﬁve sessions each that
targeted patients and caregivers individually, hand-outs
with written information and the assignment of a
contact person for each dyad for ad hoc monitoring and
follow-up. The dyads in the control group as well as in
the intervention group received follow-up visits at 3, 6,
12 and 36 months after randomisation. This means that
both groups, in addition to usual care and the psycho-
social intervention for those randomised to intervention,
also received a follow-up intervention. At the assessments
at 6 and 12 months, the raters were instructed to accom-
modate the patient’s and the caregiver’s typical frustra-
tion and uncertainty associated with a recent diagnosis
by providing overall information and guidance, and they
could facilitate contact with the relevant local support
programmes.
Costs
Measurement of resource use was conducted from a
societal perspective and was valued using opportunity
costs to estimate the long-term average costs of providing
the intervention on a routine basis. All costs were valued
according to the price year 2008 and converted into
EURO. The following is a summary of the methodology
for establishing the cost parameter, which has been
detailed in a separate report.13
The intervention cost was estimated from a microcost-
ing procedure based on case reports with detailed time
registrations, which were valued using loaded wage
tariffs for health professionals. The microcosting proced-
ure has also been reported in detail elsewhere.14
The costing of healthcare was based on national regis-
ters for service utilisation in the primary and secondary
healthcare sectors. Tariffs of national agreements
between Local Government Denmark and the respective
professional associations (primary care) and tariffs of the
Diagnostic-related-grouping (DRG) case-mix system (sec-
ondary care) were used for valuation.15
Events and duration of institutionalisation (in days)
were extracted from national registries and validated by
telephone interviews with relatives immediately after the
end of the trial (eg, if the registers indicated that the
patient had moved during the course of the trial). The
item cost for a day at a nursing home was adapted from
a large Swedish costing study that estimated the annual
cost at 2005-SEK 472 579 (2008-EUR 84 225).16
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The Resource Utilisation in Dementia questionnaire17
was administered to caregivers at baseline and at 6, 12
and 36 months after randomisation to monitor informal
care and associated production loss. The questionnaire
generally asked the respondent how much time was spent
on a speciﬁc activity on a typical day and also the monthly
frequency of such typical days. Accordingly, the total
amount of time per month was calculated by multiplying
these two measures, whereas the total for the whole study
period was estimated using a linear interpolation
between observations. Informal care and production loss
were valued using opportunity cost of the caregivers’
time, which was estimated from national age-matched
and gender-matched net and gross wages, respectively.
Utility
The EuroQoL 5-dimensions (EQ-5D) was administered
to caregivers at baseline and at 6, 12 and 36 months of
follow-up for reporting of caregivers’ health-related
quality of life and for proxy reporting of patients’
health-related quality of life.18 The collected descriptive
classiﬁcations were converted into health utilities using
the Danish scoring algorithm.19
QALYs were estimated individually for the patient and
the caregiver as the area under the health utility curve
over time using linear interpolation between observa-
tions, or between the last observation and zero if an indi-
vidual was censored because of death. Lifetime was
measured in days based on register data from the
national registry of death causes.20
Missing data
Missing data on the questionnaire-based cost categories
(informal care and production loss) and on the
EQ-5D-based health utility scores were replaced using
multiple imputation, which is generally used to address
data missing at random.21 This method allows for uncer-
tainty about missing data by creating, and appropriately
combining the results from each of a number of differ-
ent sets of plausible imputed data. It should be noted
that the remaining cost categories (healthcare and insti-
tutionalisation) were based on administrative national
registers with full coverage and were thus not subject to
imputation. Additionally, it should be noted that costs
and health utility were inherently zero from the time of
death (which was identiﬁed from administrative regis-
ters) and that imputation also did not apply to these cir-
cumstances. During the follow-up, 66 dyads were
censored because of the death of the patient or the care-
giver; 40 dyads were in the intervention group and 26
were in the control group. The censoring was caused by
patient death in 51 cases (34 in the intervention group
and 17 in the control group) and caregiver death in 15
cases (6 in the intervention group and 9 in the control
group). These numbers were different from those
reported in the clinical report where dyads were cen-
sored because of death only if the patient died.8
Because all values missing as a result of death were
scored as zero, the combined response rates of all cost
variables and all health utility variables (for both
members of each dyad) were 70% in the intervention
group and 74% in the control group.
Logistic regression was used to identify the baseline
characteristics that varied systematically between the
responders and non-responders, which were used in the
imputation procedure along with the non-missing
responses. The baseline characteristics that were used as
covariates included the following: age and gender of the
patient, age and gender of the caregiver, whether the
caregiver was working and the geographical afﬁliation of
the dyad (ie, the particular centre in this multicentre
study). Imputations were produced using the chained
equation approach22 because the non-response was of a
non-monotonic character (eg, non-respondents at time
point one could return and become responders at time
point two). The distributions for the incomplete cost cat-
egories were skewed and had a semicontinuous distribu-
tion, and a large proportion of patients had zero cost.
These variables were split into the following two vari-
ables before imputation: a binary variable indicating
whether the cost was zero and a log-transformed con-
tinuous variable for the actual cost when it was non-zero.
Values for the binary and continuous variables were
imputed and then multiplied to provide an imputed
cost. The health utility scores were imputed on their ori-
ginal scale. Logistic regression was used to impute the
binary variable of resource use and truncated linear
regression was used to ensure that the imputations of
the continuous variables of the costs and health utilities
were within plausible ranges (eg, health utility was
bound between −0.6 and 1). Twenty imputations were
generated. After imputation, the complete cost data
were transformed back to the original scale prior to the
main analysis.
Cost utility evaluation
The cost utility evaluation was based on the standard
methodology where costs and QALYs accrued over the
follow-up period for each dyad were ﬁrst quantiﬁed as
individual parameters and then transformed into net
beneﬁt in order to estimate the cost-effectiveness of the
psychosocial approach over the usual practice. The net
beneﬁt was estimated by valuing each dyad’s QALY gain,
using a range of hypothetical threshold values for
decision-makers’ willingness to pay for a QALY (from £0
to £100 000) and subtracting the observed cost for the
dyad. Both costs and QALYs were discounted at an
annual rate of 3% (which is the consensus-based stand-
ard rate used in evaluations of Danish healthcare
programmes).
The statistical analysis of the individual parameters
and of the net beneﬁt was based on non-parametric
bootstrapping (10 000 replications) due to the skewed
nature of the data.23 For the QALY parameter, an adjust-
ment for health utility at baseline was made to control
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for an average difference between the groups that was a
result of statistical variation and not the treatment alloca-
tion.24 The adjustment was made by including baseline
utility in regression models of treatment allocation on
costs and QALYs, respectively.
Cost-effectiveness acceptability curves were used to
illustrate the probability of the intervention being cost-
effective for the range of threshold values for willingness
to pay for a QALY.25 26 An alternative scenario analysis
was conducted to test the methodological uncertainty of
the imputation procedure, the choice of the cost per-
spective and the adjustment for baseline skewness of the
randomisation. The impacts of these alternative scen-
arios were also illustrated using cost-effectiveness accept-
ability curves. All analyses were conducted using Stata
V.12.1 for Mac.
RESULTS
Costs and QALY differences
The provision of early psychosocial intervention for
patients with AD and their primary caregivers was esti-
mated to incur an additional average cost of €3401. This
estimate masked bidirectional tendencies, because cost
savings were observed for the healthcare sector and for
nursing home placement, whereas higher costs were
observed for informal care. However, none of these ﬁnd-
ings were statistically signiﬁcant. Table 1 details the costs
of intervention, including the estimates of the complete
case analysis, which led to even higher estimates for
informal care. The higher estimates can be partly
explained by the working status of caregivers with incom-
plete data, as they were often full-time workers and
accordingly could not provide as many informal care
hours as caregivers outside the labour force.
In terms of QALY, no statistically signiﬁcant differences
were observed between the groups. On average,
however, the patients and caregivers in the intervention
group reported lower scores than their counterparts in
the control group. The lower scores were, to some
extent, the result of a signiﬁcant difference (p<0.05)
that already existed at baseline, which was controlled for
in the reported differences of table 2. After adjustment
for this baseline difference, the overall impact of the psy-
chosocial intervention was estimated at an average nega-
tive value of 0.06. The results of the complete case
analysis supported the direction of this ﬁnding, although
the ﬁndings based on complete cases were more
extreme and led to a statistically signiﬁcant (p<0.05)
negative value of 0.38. Figure 1 details the health utility
scores over time and the impact of multiple imputations
on the average values.
Cost-effectiveness
Given that the intervention did not seem to generate
QALY gains or cost savings, the potential for cost-
effectiveness was limited. The statistical uncertainty sur-
rounding these parameters, however, means that cost-
effectiveness cannot be ruled out until the combined
uncertainty has been examined. Figure 2 shows the
probability of the intervention being cost-effective at a
continuum of hypothetical threshold values for decision-
makers’ willingness to pay for an additional QALY. The
curves declined for increasing threshold values because
of the typical observation that the intervention led to a
negative QALY gain. The probability for cost-
effectiveness did not exceed 36% for the imputation-
based analysis and 14% for the complete case analysis
over the range of threshold values.
Alternative scenario analysis
A ﬁnal set of uncertainties related to the main ﬁnding
involved methodological uncertainties. Figure 3 shows
the impact of alternative scenarios on the cost-
effectiveness acceptability curves. The scenario most
Table 1 Costs of care for dyads randomised to psychosocial intervention or control during 3 years of follow-up (€)
Psychosocial intervention Control Difference*
n Mean (SE) n Mean (SE) Mean (SE)
Complete case analysis
Intervention 92 1088 (29) 103 0 1088 (29)
Healthcare services 92 11 472 (1249) 103 14 546 (1521) −3074 (1983)
Nursing homes 92 21 217 (5329) 103 20 189 (4092) 1029 (6708)
Informal care 92 63 092 (10 701) 103 46 931 (7670) 16 161 (13 246)
Production loss 92 2823 (1040) 103 2679 (886) 144 (1362)
Total cost 92 99 692 (11 528) 103 84 344 (8594) 15 348 (14 401)
Multiple imputation-based analysis
Intervention 163 1031 (26) 167 0 1031 (26)
Healthcare services 163 13 597 (1196) 167 15 069 (1562) −1472 (1976)
Nursing homes 163 20 412 (3713) 167 24 404 (3577) −3992 (5131)
Informal care 163 46 557 (6346) 167 38 510 (4909) 8047 (8066)
Production loss 163 2545 (631) 167 2758 (605) −214 (882)
Total cost 163 84 142 (6992) 167 80 741 (6029) 3401 (9216)
*None of the differences were statistically significant (p<0.05).
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likely to affect the main ﬁnding was a restriction to a
cost perspective for formal care (ie, health-care and
nursing home placement). In this scenario, the
maximum probability for cost-effectiveness reached 78%
for a zero threshold. Cost savings drove this probability,
and it should be noted that the probability decreased
for any value put on a QALY.
DISCUSSION
This study assessed the cost-effectiveness of early psycho-
social intervention in patients with AD. The main
ﬁnding was that a psychosocial intervention is unlikely to
be cost-effective in a Danish setting because it did not
generate additional QALYs and it led to higher average
usage of informal care.
Strengths and weaknesses of the study
The cost utility evaluation was conducted alongside a
well-characterised clinical trial5 that represented one of
the ﬁrst large-scale randomised controlled trials con-
ducted in strict adherence to the CONSORT guideline.
Furthermore, it is the ﬁrst report on the long-term
cost-utility of a psychosocial intervention. Despite the
usual challenges associated with assessing the effects of
social care aimed at community-dwelling individuals,
relatively high response rates were obtained. The
responses were supported with detailed register data
from national registries to provide a comprehensive data
set that had been thoroughly analysed and separately
interpreted before it was synthesised in this
paper.5 6 8 13 14
Informal care appeared to play an important role in
the analysis of cost-effectiveness. Although it did not
drive the main ﬁnding alone, the validity of the meas-
urement of informal care warrants some consideration.
A validated and well-known instrument17 was used for
the measurement of informal care; however, it can be
difﬁcult to obtain unbiased estimates for a number of
reasons. First, caregivers may not consider their life
together with the person with dementia as service provi-
sion. Second, it is not possible over long periods of
follow-up to monitor status with a frequency that rules
out recall and interpolation bias. Third, there is much
controversy regarding the valuation of informal care.27
However, it should be noted that even a zero valuation
of informal care would not have altered the main
ﬁnding.
The measurement of QALYs is similarly challenged by
the long period of follow-up and the fact that the
patient and the caregiver were subject to measurement.
The health utility of the patients was proxy rated, which
has been shown to potentially imply an underestima-
tion.28 However, in this study there was no signiﬁcant
effect of the DAISY intervention on any quality of life
measure. Based on results in a previous report29 we
found that proxy rated quality of life probably better
reﬂects progression of clinical measures as compared to
patient-rated measures, and that EQ-5D is a suitable
alternative to disease-speciﬁc quality of life measures in
research. Additionally, it was assumed that the average
trend between the observation points was linear.
Although this is a standard practice in economic evalu-
ation, AD could be a special case because of the disease
progress and/or the ability of the caregiver to cope
being non-linear for the observation points chosen in
the present design. Nonetheless, any bias in the
reported QALYs would have to affect the groups differ-
ently to weaken the validity of the analytical ﬁndings.
Patients in the intervention group had higher mortal-
ity than those in the control group although this
increased mortality was unlikely to be caused by the
intervention, as the nature of the intervention pro-
gramme did not subject the patients to any health risk.
At baseline, the quality of life of the patients in the inter-
vention group was rated as poorer than that of the
control group, by the patients themselves and by their
caregivers. There were small insigniﬁcant differences in
socioeconomic and clinical variables which could be
associated with the higher mortality rate in the interven-
tion group. More patients in the intervention group
lived alone (4% difference), rented their house (7% dif-
ference), had more comorbidities (4.4% difference)
and were diagnosed with mixed AD and vascular




n Mean (SE) n Mean (SE) Mean (SE)
Complete case analysis
Patient QALY 101 1.43 (0.07) 113 1.67 (0.05) −0.17 (0.07)*
Caregiver QALY 101 2.04 (0.07) 113 2.24 (0.06) −0.19 (0.09)*
Total QALY 101 3.47 (0.13) 113 3.92 (0.09) −0.38 (0.14)*
Multiple imputation-based analysis
Patient QALY 163 1.34 (0.05) 167 1.48 (0.05) −0.06 (0.06)
Caregiver QALY 163 1.92 (0.06) 167 1.98 (0.06) −0.03 (0.08)
Total QALY 163 3.26 (0.10) 167 3.46 (0.10) −0.09 (0.13)
†Differences are adjusted for baseline utility. Statistically significant differences are marked by *(p<0.05).
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dementia (4.2% difference). Whether these differences
could contribute to the higher mortality in the interven-
tion group is uncertain.
The validity of the imputation procedure was based on
the assumption that the data were missing at random,
that is, that non-response was completely random when
adjusted for observed covariates. A number of covariates
appeared to explain the non-response and these covari-
ates were associated with substantially lower health utility
scores almost consistently over the entire follow-up
period. This is shown in ﬁgure 1 where the inﬂuence of
taking this appropriately into account is demonstrated to
lower the average scores of both randomisation groups.
The missing-at-random assumption was tested by a series
of regressions of the parameters with missing values on
the covariates used in the multiple imputation proced-
ure and a dummy for whether a respondent had ≥1
missing values. The fact that ‘missingness’ was not
Figure 1 Observed health utility scores in the intervention and control groups: the panels show the values for (A) patients and
(B) caregivers.
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associated with the observed parameter values in any of
these regressions gives some credibility that the ‘missing-
ness’ is fully controlled for.
For ethical reasons the study design included a
minimum of support for the control group in relation to
the systematic assessment of their status at 6 and
12 months post randomisation. This is not a perfect
reﬂection of the usual practice and could have led dyads
in the control group to perform better than they would
have without this minimum level of support.
Comparison with other studies
This study appears to be the ﬁrst of its kind in assessing
the long-term consequences of psychosocial intervention
in mild AD. There have been, however, a few cost-
effectiveness evaluations on related therapies. A Dutch
study investigated the cost-effectiveness of occupational
therapy for patients with mild to moderate AD and for
their primary caregivers.30 The study concluded that
occupational therapy was cost-effective due to reducing
the amount of informal care within the 3 months
follow-up time. A recent UK study concluded that an
intervention based on reminiscence groups was not cost-
effective, based on a cost perspective restricted to
selected formal care.31 Finally, two Markov model-based
studies have been reported. In a Finnish study on the
cost-effectiveness of a family-support programme it was
concluded that family support could be cost-effective
because of overall cost savings.32 In a North American
study the net beneﬁt of three experimental management
strategies in comparison with the usual care was assessed:
pharmacological treatment, caregiver support and a com-
bination of the two.33 Positive net beneﬁts were identiﬁed
for all of the experimental strategies and, in particular,
the combined strategy provided a net beneﬁt of up to
$94 000 for a typical person with mild AD.
Limitations and implications for practice
In an assessment of external validity, it should be consid-
ered whether caregivers could have a higher or a lower
need for intervention than in the present structural and
cultural setting. The present setting is representative of a
country with one of the world’s largest public sectors
where citizens have free access to a range of public ser-
vices that could, to some extent, reduce the need for
(extra) tailored support. In addition, Danish citizens are
relatively well educated, and it is common for men and
women to participate in the labour force. It is the
authors’ belief that the main ﬁndings are generalisable
to other (North) European countries, especially those
with a National Health Service system, whereas the
descriptive costs cannot be expected to be generalisable
across settings.
Given the negative ﬁnding of this study, which seems
to be scientiﬁcally robust despite the challenges of con-
ducting experimental research in the community
setting, a recommendation for practice in settings that
are similar to the Danish setting is to provide a follow-up
with referral to available local support programmes
when needed and to restrict large multifaceted interven-
tion programmes to patients and caregivers with special
needs until further evidence for cost-effectiveness
emerges.
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